ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ardelyx has agreed to license its phosphate transport NaP2b inhibitor program to Sanofi for an undisclosed up-front sum. The deal includes development and regulatory milestones that could be worth $198 million. The inhibition of NaP2b should be useful for treating hyperphosphatemia, or elevated serum phosphate, in patients with chronic kidney disease, according to Ardelyx. Sanofi will have responsibility for development efforts. “Sanofi’s R&D and commercial capabilities in phosphate management are rivaled by no other company,” says Ardelyx CEO Mike Raab.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X